Genovis AB Series B | Cash Flow

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
15,985.60
20,471.20
19,824.40
14,770.10
7,937.60
Depreciation, Depletion & Amortization
1,113.60
1,274.30
1,318.80
1,293.90
1,280.70
Other Funds
11,633.70
-
-
-
-
Funds from Operations
14,800.50
19,056.30
14,832.10
13,595.00
6,657.10
Changes in Working Capital
2,332.70
3,136.00
1,285.20
2,480.10
1,698.00
Net Operating Cash Flow
12,467.80
22,192.30
16,117.30
16,075.10
8,355.10
Capital Expenditures
2,369.40
3,043.30
1,686.00
1,437.40
1,763.20
Purchase/Sale of Investments
3,000.00
2,000.00
5,000.00
-
-
Net Investing Cash Flow
5,369.40
5,043.30
3,314.00
1,437.40
1,763.20
Issuance/Reduction of Debt, Net
-
225.80
-
2,500.00
-
Net Financing Cash Flow
11,633.70
27,443.90
14,167.00
19,741.40
10,754.70
Net Change in Cash
6,203.50
208.30
1,363.70
2,228.80
636.40
Free Cash Flow
13,705.80
23,432.70
16,306.50
16,085.50
8,810.80
Change in Capital Stock
-
27,218.00
14,167.00
17,241.40
10,754.70

About Genovis AB

View Profile
Address
Scheelevägen 2
Lund SN 220 07
Sweden
Employees -
Website http://www.genovis.com
Updated 09/14/2018
Genovis AB engages in the development and market of nanotechnology. It develops, produces and markets technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The company was founded by Inga Sarah Maria Fredriksson in 1999 and is headquartered in Lund, Sweden.